Related Experiment Video

Updated: Jun 28, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways

Nitin Chakravarti1, Amy Boles2, Rachel Burzinski2

  • 1Division of Hematologic Malignancies, Sidney Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 328, Philadelphia, PA, 19107, USA. nitin.chakravarti@jefferson.edu.

Scientific Reports
|April 23, 2024
PubMed

Insights

Exportin 1 (XPO1) inhibition with KPT-330 shows promise for Cutaneous T-cell lymphoma (CTCL). This XPO1 inhibitor reduced tumor growth and improved survival in preclinical models, suggesting a new therapeutic avenue for CTCL patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dysregulated nuclear-cytoplasmic transport is implicated in cancer.
  • Exportin 1 (XPO1) inhibitors, like KPT-330, are approved for other hematological malignancies.
  • Cutaneous T-cell lymphoma (CTCL) has limited treatment options for advanced stages.

Purpose of the Study:

  • To investigate the efficacy of XPO1 inhibition using KPT-330 in CTCL.
  • To elucidate the molecular mechanisms of KPT-330 action in CTCL cells.

Main Methods:

  • Analysis of XPO1 expression in CTCL cells.
  • In vitro studies assessing KPT-330's effects on cell proliferation, cell cycle, and apoptosis.
  • RNA-sequencing to identify affected pathways.
  • In vivo studies using a CTCL xenograft mouse model.

Main Results:

  • XPO1 expression is upregulated in CTCL.
  • KPT-330 inhibited CTCL cell proliferation, induced G1 cell cycle arrest, and promoted apoptosis.
  • RNA-seq revealed enrichment of cell cycle and p53 pathway genes.
  • KPT-330 suppressed XPO1, upregulated tumor suppressors (p53, p21, p27), and downregulated Survivin.
  • In vivo, KPT-330 blocked tumor growth and prolonged survival.

Conclusions:

  • KPT-330 demonstrates significant anti-tumor activity in preclinical CTCL models.
  • Targeting XPO1 with KPT-330 warrants further investigation for CTCL treatment.
  • XPO1 inhibition impacts key cell cycle and apoptosis pathways in CTCL.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

405

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K